[In vitro interaction of tazobactam/piperacillin combined with aminoglycosides against Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli AND Staphylococcus aureus].
The in vitro combination effect of tazobactam/piperacillin (TAZ/PIPC) with aminoglycosides (amikacin (AMK) and isepamicin (ISP)) were investigated by the checkerboard dilution method against PIPC-resistant and TAZ/PIPC-susceptible Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli and Methicillin-sensitive Staphylococcus aureus (MSSA). The following results were obtained. 1. The combination of TAZ/PIPC with AMK showed synergistic effect for 66.7% of P. aeruginosa and 9.1% of K. pneumoniae and additive effect for 76.9% of E. coli and 74.1% of MSSA. The antagonistic effect of TAZ/PIPC with AMK was not demonstrated for all tested strains. 2. The combination of TAZ/PIPC with ISP showed synergistic effect for 61.9% of P. aeruginosa and 22.7% of K. pneumoniae and additive effect for 84.6% of E. coli and 66.7% of MSSA. The antagonistic effect of TAZ/PIPC with ISP was not demonstrated for all tested strains. In conclusion, these results suggest that the combination therapies of TAZ/PIPC with aminoglycosides are useful for the clinical treatment of sepsis caused by above four species.
Yamada
Hiroshi
H
Research Laboratories, Toyama Chemical Co., Ltd., 4-1, Shimookui 2-chome, Toyama 930-8508, Japan.
Takahata
Masahiro
M
Minami
Shinzaburo
S
D000583:Amikacin / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D004336:Drug Antagonism; D004338:Drug Combinations; D024881:Drug Resistance, Bacterial; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D004926:Escherichia coli / Q000187:drug effects*; D005839:Gentamicins / Q000008:administration & dosage*; D008826:Microbial Sensitivity Tests; D010397:Penicillanic Acid / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D010406:Penicillins / Q000008:administration & dosage*; D010878:Piperacillin / Q000008:administration & dosage*; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D013211:Staphylococcus aureus / Q000187:drug effects*; D000078142:Tazobactam
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D004791:Enzyme Inhibitors; D005839:Gentamicins; D010406:Penicillins; D000583:Amikacin; D010397:Penicillanic Acid; C016927:isepamicin; D000078142:Tazobactam; D010878:Piperacillin